Lerkanidipin Zentiva

Lercanidipine, the active ingredient in Lerkanidipin Zentiva, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension, helping to reduce cardiovascular risk.

GNH USA supplies Lerkanidipin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured medication to hospitals, pharmacies and clinics worldwide. Our distribution network adheres to global standards, facilitating reliable access across multiple regions.

Lercanidipine is a calcium channel blocker used in the management of hypertension.

Hypertension: reduction of systolic and diastolic blood pressure, improving cardiovascular outcomes.

Lercanidipine may cause several adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient warmth and redness of the skin, especially on the face. - Peripheral edema: swelling of the lower limbs due to fluid accumulation. - Dizziness: sensation of light‑headedness, particularly when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting. - Angioedema: rapid swelling of the face, lips, tongue, or throat, potentially compromising airway. - Hepatotoxicity: rare liver injury manifested by elevated enzymes or jaundice.

When prescribing or dispensing Lercanidipine, several safety considerations should be observed.

Monitor blood pressure: adjust therapy based on regular measurements. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Caution in hepatic impairment: dose may need adjustment due to metabolism reliance on the liver. Use with caution in elderly patients: increased sensitivity to vasodilatory effects. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels leading to excessive hypotension. - Co‑administration with other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause additive blood‑pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin) may reduce drug exposure and effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may blunt the antihypertensive response. - Grapefruit juice may increase systemic exposure, requiring careful monitoring.